Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies

References

• Meyer H, Bossert F, Vater W, Stoepel K. Bayer AG. DOS 2117571, 1972. Chem Abtrs. 1973; 78: 16038
   Google Scholar
• Meyer H, Bossert F, Kazda S, Hoffmeister F, Vater W. Bayer AG, DOS 2815578. Chem Abtrs 1979
   Google Scholar
• Nowychy MC, Fox A, Tsien RW. Three types of calcium channel with different calcium agonist sensitivity. Nature 1985; 316: 440–443
   PubMed Web of Science ®Google Scholar
• Dockerty RJ, Brown RJ. Interaction of 1,4 dihydropyridines with somatic Ca2+ currents in hippocampal CA1 neurons of the guinea pig in vitro. Neuroscience Letters. 1986; 10: 106–109
   Google Scholar
• Alborch E, Salom JB, Torregrosa G. Calcium channels in cerebral arteries. Pharmacol Ther. 1995; 68: 1–34
   PubMed Web of Science ®Google Scholar
• Scriabine A, van den Kerckhoff W. Pharmacology of nimodipine. A review. Ann NY Acad Sci. 1988; 522: 698–706
   PubMed Web of Science ®Google Scholar
• Towart R, Perzborn E. Nimodipine inhibits carbocyclic thromboxane-induced contractions of cerebral arteries. Eur J Pharmacol. 1981; 69: 213–215
   PubMed Web of Science ®Google Scholar
• Towart R, Wehinger E, Meyer H, Kazda S. The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneimittelforschung. 1982; 32: 338–346
   PubMed Web of Science ®Google Scholar
• Kazda S. Pharmacology of nimodipine, a calcium antagonist with preferential cerebrovascular activity. Neurochirurgia. 1985; 28: 70–73
   PubMedGoogle Scholar
• Wadworth AN, McTavish D. Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders. Drugs Aging. 1992; 2: 262–286
   PubMed Web of Science ®Google Scholar
• Auer LM, Oberbauer RW, Schalk HV. Human pial vascular reactions to intravenous nimodipine-infusion during EC-IC bypass surgery. Stroke. 1983; 14: 210–213
   PubMed Web of Science ®Google Scholar
• Takayanagi I, Koike K, Miyake N, Sato R, Yamada K. Selectivity of cerebral vasodilators on basilar arteries. Gen Pharmacol. 1986; 17: 505–507
   PubMedGoogle Scholar
• Zabramski J, Spetzler RF, Bonstelle C. Chronic cerebral vasospasm: Effect of calcium antagonists. Neurosurgery. 1986; 18: 129–135
   PubMed Web of Science ®Google Scholar
• Catterall WA, Striessnig J. Receptor sites for Ca2+ channel antagonists. Trends Pharmacol Sci. 1992; 13: 256–262
   PubMed Web of Science ®Google Scholar
• Barker FG, II, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: A metaanalysis. J Neurosurg. 1996; 84: 405–414
   PubMed Web of Science ®Google Scholar
• Vermeulen M. Subarachnoid haemorrhage: Diagnosis and treatment. J Neurol. 1996; 243: 496–501
   PubMed Web of Science ®Google Scholar
• Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998; 50: 876–883
   PubMed Web of Science ®Google Scholar
• Rasmussen G, Bergholdt B, Dalh B, Sunde N, Cold G, Voldby B. Effect of nimodipine on cerebral blood flow and cerebrovascular reactivity after subarachnoid haemorrhage. Acta Neurol Scand. 1999; 99: 182–186
   PubMed Web of Science ®Google Scholar
• Tajima A, Hans FJ, Livingstone D, Wei L, Finnegan W, DeMaro J, Fenstermacher J. Smaller local brain volumes and cerebral atrophy in spontaneously hypertensive rats. Hypertension. 1993; 21: 105–111
   PubMed Web of Science ®Google Scholar
• Amenta F, Strocchi P, Sabbatini M. Vascular and neuronal hypertensive brain damage: Protective effect of treatment with nicardipine. J Hypertens 1996; 14(Suppl.)29–35
   Google Scholar
• Sabbatini M, Strocchi P, Vitaioli L, Amenta F. Microanatomical changes of intracerebral arteries in spontaneously hypertensive rats: A model of cerebrovascular disease of the elderly. Mech Ageing Dev. 2001; 122: 1257–1268
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Tomassoni D, Amenta F. Hypertensive brain damage: Comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats. Mech Ageing Dev. 2001; 122: 2085–2105
   PubMed Web of Science ®Google Scholar
• Deyo RA, Straube KT, Disterhoft JF. Nimodipine facilitates associative learning in aging rabbits. Science. 1989; 243: 809–811
   PubMed Web of Science ®Google Scholar
• Nomura M. Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats. Arzneimittelforschung. 1988; 38: 1282–1286
   PubMed Web of Science ®Google Scholar
• Scriabine A, Schuurman T, Traber J. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J. 1989; 3: 1799–1806
   PubMed Web of Science ®Google Scholar
• Levy A, Kong RM, Stillman MJ, Shukitt-Hale B, Kadar T, Rauch TM, Lieberman HR. Nimodipine improves spatial working memory and elevates hippocampal acetylcholine in young rats. Pharmacol Biochem Behav. 1991; 39: 781–786
   PubMed Web of Science ®Google Scholar
• Meneses A, Terrón JA, Ibarra M, Hong E. Effects of nimodipine on learning in normotensive and spontaneously hypertensive rats. Behav Brain Res. 1997; 85: 121–125
   PubMed Web of Science ®Google Scholar
• Kazda S, Garthoff B, Krause HP, et al. Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung. 1982; 32: 331–338
   PubMed Web of Science ®Google Scholar
• Allen GS. Role of calcium antagonists in cerebral arterial spasm. Am J Cardiol. 1985; 55: 149–153
   Google Scholar
• Freedman DD, Waters DD. “Second generation” dihydropyridine calcium antagonists: Greater vascular selectivity and some unique applications. Drugs. 1987; 34: 578–598
   PubMed Web of Science ®Google Scholar
• Brandt L, Andersson KE, Ljunggren B, et al. Cerebrovascular and cerebral effects of nimodipine—an update. Acta Neurochir. 1988; 45: 11–20
   Google Scholar
• Langley MS, Sorkin EM. Nimodipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989; 37: 669–699
   PubMed Web of Science ®Google Scholar
• Peroutka SJ, Banghart SB, Allen GS. Relative potency and selectivity of calcium antagonists used in the treatment of migraine. Headache. 1984; 24: 55–58
   PubMed Web of Science ®Google Scholar
• Ramsch KD, Ahr G, Tettenborn D, et al. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia. 1985; 28: 74–78
   PubMedGoogle Scholar
• Gengo FM, Fagan SC, Krol G, et al. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. Br J Clin Pharmacol. 1987; 23: 47–53
   PubMed Web of Science ®Google Scholar
• Ramsch KD, Lücker PW, Wetzelsberger N. Pharmacokinetics of intravenously and orally administered nimodipine. Clin Pharmacol Ther. 1987; 42: 217
   Google Scholar
• Kirch W, Hutt HJ, Heidemann H, et al. Drug interactions with nitrendipine. J Cardiovasc Pharmacol 1984; 6: S982–S985
   PubMed Web of Science ®Google Scholar
• Ramsch KD, Graefe KH, Scherling D, et al. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol. 1986; 6: 73–80
   PubMed Web of Science ®Google Scholar
• Vinge E, Andersson KE, Brandt L, et al. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid hemorrhage. Eur J Clin Pharmacol. 1986; 30: 421–425
   PubMed Web of Science ®Google Scholar
• Muck W, Ahr G, Kuhlmann J. Nimodipine. Potential for drug-drug interactions in the elderly. Drugs Aging. 1995; 6: 229–242
   PubMed Web of Science ®Google Scholar
• Uematsu D, Greenberg JH, Hickey WF, Reivich M. Nimodipine attenuates both increase in cytosolic free calcium and histologic damage following focal cerebral ischemia and reperfusion in cats. Stroke. 1989; 20: 1531–1537
   PubMed Web of Science ®Google Scholar
• Steen PA, Gisvold SE, Milde JH, Newberg LA, Scheithauer BW, Lanier WL, Michenfelder JD. Nimodipine improves outcome when given after complete cerebral ischemia in primates. Anesthesiology. 1985; 62: 406–414
   PubMed Web of Science ®Google Scholar
• Horn J, de Haan RJ, Vermeulen M, Luiten PG, Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia: A systematic review. Stroke. 2001; 32: 2433–2438
   PubMed Web of Science ®Google Scholar
• Araki H, Hino N, Karasawa Y, Kawasaki H, Gomita Y. Effect of calcium channel blockers on cerebral ischemia-induced hyperactivity in Mongolian gerbils. Physiol Behav. 1999; 67: 573–577
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Henshall DC, Simon RP. Parallel dose-response studies of the voltage-dependent Na+ channel antagonist BW619C89, and the voltage-dependent Ca2+ channel antagonist nimodipine, in rat transient focal cerebral ischaemia. Eur J Pharmacol. 1999; 364: 99–105
   PubMed Web of Science ®Google Scholar
• Zhu D, Li R, Liu G, Hua W. Nimodipine inhibits calcium-independent nitric oxide synthase activity in transient focal cerebral ischemia rats and cultured mouse astroglial cells. Life Sci. 1999; 65: 221–231
   Web of Science ®Google Scholar
• Chen YH, Du GH, Zhang JT. Salvianolic acid B protects brain against injuries caused by ischemia-reperfusion in rats. Acta Pharmacol Sin. 2000; 21: 463–466
   PubMed Web of Science ®Google Scholar
• Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HW, Frick R, Muljana L, Piek J, Yonekawa Y, Gaab MR. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev. 2000; 23: 145–150
   PubMed Web of Science ®Google Scholar
• Taya K, Watanabe Y, Kobayashi H, Fujiwara M. Nimodipine improves the disruption of spatial cognition induced by cerebral ischemia. Physiol Behav. 2000; 70: 19–25
   PubMed Web of Science ®Google Scholar
• Ildan F, Gocer AI, Tuna M, Polat S, Kaya M, Isbir T, Cetinalp E. The effects of the pre-treatment of intravenous nimodipine on Na(+)-K+/Mg+2 ATPase, Ca+2/Mg+2 ATPase, lipid peroxidation and early ultrastructural findings following middle cerebral artery occlusion in the rat. Neurol Res. 2001; 23: 96–104
   PubMed Web of Science ®Google Scholar
• Liu XD, Pan GY, Xie L, Hou YY, Lan W, Su Q, Liu GQ. Cyclosporin A enhanced protection of nimodipine against brain damage induced by hypoxia-ischemia in mice and rats. Acta Pharmacol Sin. 2002; 23: 225–229
   PubMed Web of Science ®Google Scholar
• Sobrado M, Lopez MG, Carceller F, Garcia AG, Roda JM. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 2003; 118: 107–113
   PubMed Web of Science ®Google Scholar
• Yanpallewar SU, Hota D, Rai S, Kumar M, Acharya SB. Nimodipine attenuates biochemical, behavioral and histopathological alterations induced by acute transient and long-term bilateral common carotid occlusion in rats. Pharmacol Res. 2004; 49: 143–150
   PubMed Web of Science ®Google Scholar
• Bogaert L, O'Neill MJ, Moonen J, Sarre S, Smolders I, Ebinger G, Michotte Y. The effects of LY393613, nimodipine and verapamil, in focal cerebral ischaemia. Eur J Pharmacol. 2001; 411: 71–83
   PubMed Web of Science ®Google Scholar
• Zeng LH, Zhang WP, Wang RD, Wang PL, Wei EQ. [Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice.]. Yao Xue Xue Bao. 2001; 36: 148–150
   PubMedGoogle Scholar
• Shin CY, Lee NI, Je HD, Kim JS, Sung JH, Kim DS, Lee DW, Bae KL, Sohn UD. Cardiovascular responses and nitric oxide production in cerebral ischemic rats. Arch Pharm Res. 2002; 25: 697–703
   PubMed Web of Science ®Google Scholar
• Gomi S, Burnett MG, Karp A, Greenberg JH. Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia. Exp Brain Res. 2004; 155: 469–476
   PubMed Web of Science ®Google Scholar
• Yamada S, Uchida S, Naito T, Urayama A, Kimura R, Murakami Y, Matsumoto K, Watanabe H. Increase in receptor binding affinity for nimodipine in the rat brain with permanent occlusion of bilateral carotid arteries. Life Sci. 2000; 66: 1351–1357
   PubMed Web of Science ®Google Scholar
• Sorrenti V, Di Giacomo C, Renis M, Russo A, La Delfa C, Perez-Polo JR, Vanella A. Lipid peroxidation and survival in rats following cerebral post-ischaemic reperfusion: Effect of drugs with different molecular mechanisms. Drugs Exp Clin Res. 1994; 20: 185–189
   PubMedGoogle Scholar
• Liu C, Zhou R, Sun S. Nimodipine modulates Bcl-2 and Bax mRNA expression after cerebral ischemia. J Huazhong Univ Sci Technolog Med Sci. 2004; 24: 170–172
   PubMedGoogle Scholar
• Ozkan U, Aydin MD, Kemaloglu MS, Yilmaz F, Aydin IH. Effect of nimodipine on histological alterations in basilar artery following the bilateral common carotid artery ligation (preliminary study). Acta Medica (Hradec Kralove). 2004; 47: 7–12
   PubMedGoogle Scholar
• Siesjo BK. Historical overview. Calcium, ischemia, and death of brain cells. Ann NY Acad Sci. 1988; 522: 638–661
   PubMed Web of Science ®Google Scholar
• Pisani A, Calabresi P, Tozzi A, D'Angelo V, Bernardi G. L-type Ca2+ channel blockers attenuate electrical changes and Ca2+ rise induced by oxygen/glucose deprivation in cortical neurons. Stroke. 1998; 29: 196–201
   PubMed Web of Science ®Google Scholar
• Krieglstein J. Mechanisms of neuroprotective drug actions. Clin Neurosci. 1997; 4: 184–193
   PubMedGoogle Scholar
• Heineman U, Lux HD. Ionic changes during experimentally induced epilepsies. Research progress in epilepsy, FC Rose. Pitman Books Limited, London 1983; 87–102
   Google Scholar
• Meyer FB. Calcium, neuronal hyperexcitability and ischemic injury. Brain Res Brain Res Rev. 1989; 14: 227–243
   PubMed Web of Science ®Google Scholar
• McNamara JO. The neurobiological basis of epilepsy. Trends Neurosci. 1992; 15: 357–359
   PubMed Web of Science ®Google Scholar
• Dolin SJ, Hunter AB, Halsey MJ, Little HJ. Anticonvulsant profile of the dihydropyridine calcium channel antagonists, nitrendipine and nimodipine. Eur J Pharmacol. 1988; 152: 19–27
   PubMed Web of Science ®Google Scholar
• Speckmann EJ, Walden J, Bingmann D. Functional implication of calcium ions in epileptic seizures. Antiepileptic effects of organic calcium antagonists. Arzneimittelforschung. 1989; 39: 149–156
   PubMed Web of Science ®Google Scholar
• van Luijtelaar EL, Ates N, van der Staay FJ. The effects of chronic treatment with a calcium channel antagonist on two types of generalized epilepsies in rats. Pharmacol Biochem Behav. 1994; 48: 575–579
   PubMed Web of Science ®Google Scholar
• Kriz J, Zupan G, Simonic A. Differential effects of dihydropyridine calcium channel blockers in kainic acid-induced experimental seizures in rats. Epilepsy Res. 2003; 52: 215–225
   PubMed Web of Science ®Google Scholar
• van Luijtelaar EL, Ates N, Coenen AM. Role of L-type calcium channel modulation in nonconvulsive epilepsy in rats. Epilepsia. 1995; 36: 86–92
   PubMed Web of Science ®Google Scholar
• Zupan G, Erakovic V, Simonic A, Kriz J, Varljen J. The influence of nimodipine, nicardipine and amlodipine on the brain free fatty acid level in rats with penicillin-induced seizures. Prog Neuropsychopharmacol Biol Psychiatry. 1999; 23: 951–961
   PubMed Web of Science ®Google Scholar
• Balakrishnan S, Pandhi P, Bhargava VK. Effect of nimodipine on the efficacy of commonly used antiepileptic drugs in rats. Indian J Exp Biol. 1998; 36: 51–54
   PubMedGoogle Scholar
• O'Brien DP, Simpson ST, Longshore RC, Kroll RA, Goetze L. Nimodipine for treatment of idiopathic epilepsy in dogs. J Am Vet Med Assoc. 1997; 210: 1298–1301
   PubMed Web of Science ®Google Scholar
• Gasior M, Kaminski R, Brudniak T, Kleinrok Z, Czuczwar SJ. Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm Gen Sect. 1996; 103: 819–831
   Web of Science ®Google Scholar
• Dolin SJ, Little HJ. Augmentation by calcium channel antagonists of general anaesthetic potency in mice. Br J Pharmacol. 1986; 88: 909–914
   PubMed Web of Science ®Google Scholar
• Little HJ, Dolin SJ, Halsey MJ. Calcium channel antagonists decrease the ethanol withdrawal syndrome. Life Sci. 1986; 39: 2059–2065
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Saini HK, Garg SK. Dose-finding study with nimodipine: A selective central nervous system calcium channel blocker on aminophylline induced seizure models in rats. Brain Res Bull. 1998; 45: 495–499
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Mazurek M, Turski WA, Kleinrok Z, Czuczwar SJ. Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures. Pharmacol Biochem Behav. 2001; 68: 661–668
   PubMed Web of Science ®Google Scholar
• Paczynski RP, Meyer FB, Anderson RE. Effects of the dihydropyridine Ca2+ channel antagonist nimodipine on kainic acid-induced limbic seizures. Epilepsy Res. 1990; 6: 33–38
   PubMed Web of Science ®Google Scholar
• Höcht C, Lazarowski A, Gonzalez NN, Auzmendi J, Opezzo JA, Bramuglia GF, Taira CA, Girardi E. Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. Neurosci Lett. 2007; 413: 168–172
   PubMed Web of Science ®Google Scholar
• Firat MM, Gelebek V, Orer HS, Belen D, Firat AK, Balkanci F. Selective intraarterial nimodipine treatment in an experimental subarachnoid hemorrhage model. Am J Neuroradiol. 2005; 26: 1357–1362
   PubMed Web of Science ®Google Scholar
• Gioia AE, White RP, Bakhtian B, Robertson JT. Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm. J Neurosurg. 1985; 62: 721–728
   PubMed Web of Science ®Google Scholar
• Thomas JE, Rosenwasser RH, Armonda RA, Harrop J, Mitchell W, Galaria I. Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke. 1999; 30: 1409–1416
   PubMed Web of Science ®Google Scholar
• Ma B, Zhang J. Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage. Brain Res. 2006; 1078: 182–188
   PubMed Web of Science ®Google Scholar
• Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. BMJ. 1989; 298: 636–642
   PubMed Web of Science ®Google Scholar
• Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2005; 1: CD000277
   PubMedGoogle Scholar
• Auer LM, Ito Z, Suzuki A, et al. Prevention of symptomatic vasospasm by topically applied nimodipine. Acta Neurochir. 1982; 63: 297–302
   PubMed Web of Science ®Google Scholar
• Auer LM, Reulen HJ, Gilsbach J, . Prevention of brain infarction from arterial spasm by acute aneurysm surgery and preventive nimodipine treatment in patients with subarachnoid hemorrhage. Nimodipine: pharmacological and clinical properties, E Betz, K Deck, F Hoffmeister, et al. Schattauer Verlag, Stuttgart 1985; 397–408
   Google Scholar
• Grabowski M, Johansson BB. Nifedipine and nimodipine: Effect on blood pressure and regional cerebral blood flow in conscious normotensive and hypertensive rats. J Cardiovasc Pharmacol. 1985; 7: 1127–1133
   PubMed Web of Science ®Google Scholar
• Schmidli J, Santillan GG, Saeed M, et al. The effect of nimodipine, a calcium antagonist, on intracortical arterioles in the cat brain. Curr Ther Res. 1985; 38: 94–103
   Web of Science ®Google Scholar
• Buchheit F, Boyer P. Review of treatment of symptomatic cerebral vasospasm with nimodipine. Acta Neurochir. 1988; 45: 51–55
   Google Scholar
• Hauerberg J, Rasmussen G, Juhler M, Gjerris F. The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat. Acta Neurochir (Wien). 1995; 132: 98–103
   PubMed Web of Science ®Google Scholar
• Sun BL, Zhang SM, Xia ZL, Yang MF, Yuan H, Zhang J, Xiu RJ. The effects of nimodipine on regional cerebral blood flow, brain water and electrolyte contents in rats with subarachnoid hemorrhage. Clin Hemorheol Microcirc. 2003; 29: 337–344
   PubMed Web of Science ®Google Scholar
• Philippon J, Grob R, Dagreou F, et al. Prevention of vasospasm in subarachnoid hemorrhage: A controlled study with nimodipine. Acta Neurochir. 1986; 82: 110–114
   PubMed Web of Science ®Google Scholar
• Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients: Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988; 68: 505–517
   PubMed Web of Science ®Google Scholar
• Nimodipine for cerebral vasospasm after subarachnoid hemorrhage. Med Lett Drugs Ther. 1989; 31: 47–48
   PubMed Web of Science ®Google Scholar
• Taylor RJ. Pharmaceutical Division. Miles Inc, West Haven, CT October 12, 1989, 06516. Personal communication
   Google Scholar
• Auer LM. Preventive nimodipine and acute aneurysm surgery: Heading for the control of complications after aneurysmal subarachnoid hemorrhage. Neurochirurgia. 1985; 28: 87–92
   PubMedGoogle Scholar
• Ljunggren B, Brandt L, Saveland H, et al. Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine. Neurosurg Rev. 1987; 10: 255–263
   PubMed Web of Science ®Google Scholar
• Tettenborn D, Porto L, Ryman T, et al. Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage. Neurosurg Rev. 1987; 10: 77–84
   PubMed Web of Science ®Google Scholar
• Ljunggren B, Brandt L, Saveland H, et al. Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg. 1984; 61: 864–873
   PubMed Web of Science ®Google Scholar
• Brandt L, Ljunggren B, Saveland H, et al. Cerebral vasospasm and calcium channel blockade. Nimodipine treatment in patients with aneurysmal subarachnoid hemorrhage. Acta Pharmacol Toxicol (Copenh). 1986; 58(Suppl. 2)151–155
   PubMedGoogle Scholar
• Biller J, Godersky JC, Adams HP, Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke. 1988; 19: 1300–1305
   PubMed Web of Science ®Google Scholar
• Fieschi C, Argentino C, Toni D, et al. Calcium antagonists in ischemic stroke. J Cardiovasc Pharmacol. 1988; 12: S83–S85
   PubMed Web of Science ®Google Scholar
• Tanaka K, Gotoh F, Muramatsu F, et al. Effects of nimodipine (Bay e 9736) on cerebral circulation in cats. Arzneimittelforschung. 1980; 30: 1494–1497
   PubMed Web of Science ®Google Scholar
• Tanaka K, Gotoh F, Muramatsu F, Fukuuchi Y, Okayasu H, Suzuki N, Kobari M. Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarachnoid hemorrhage in cats. Arzneimittelforschung. 1982; 32: 1529–1534
   PubMed Web of Science ®Google Scholar
• Auer LM, Suzuki A, Yasui N, et al. Intraoperative topical nimodipine after aneurysm clipping. Neurochirurgia. 1984; 27: 36–38
   PubMedGoogle Scholar
• Pittera A, Ciancitto S. Effect of oral nimodipine on cerebral blood flow in patients with chronic cerebrovascular disorders: A supra-aortic doppler ultrasound open study. Curr Ther Res. 1990; 48: 716–729
   Web of Science ®Google Scholar
• Gaab MR, Haubitz I, Brawanski A, Korn A, Czech T. Acute effects of nimodipine on the cerebral blood flow and intracranial pressure. Neurochirurgia (Stuttg). 1985; 28: 93–99
   PubMedGoogle Scholar
• Roine RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. JAMA. 1990; 264: 3171–3177
   PubMed Web of Science ®Google Scholar
• Johnston SD, Robinson TJ. Subarachnoid haemorrhage: Difficulties in diagnosis and treatment. Postgrad Med J. 1998; 74: 743–744
   PubMed Web of Science ®Google Scholar
• van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet Jan 27, 2007; 369: 306–318
   PubMed Web of Science ®Google Scholar
• Gilsbach JM. Nimodipine in the prevention of ischaemic deficits after aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1988; 45(Suppl.)41–50
   Google Scholar
• Yasuda SU, Tietze KJ. Nimodipine in the treatment of subarachnoid hemorrhage. DICP. 1989; 23: 451–455
   PubMedGoogle Scholar
• Tucker E. Dear health care provider letter: Important drug warning regarding potential serious and life-threatening medication errors from parenteral use of Nimotop® (nimodipine capsules). From Bayer Health Care. Conn, West Haven Feb, 2006,
   Google Scholar
• Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983; 308: 619–624
   PubMed Web of Science ®Google Scholar
• Kistler JP, Ropper AH, Martin JB, Braunwald E, et al. Cerebrovascular diseases. Harrison's principles of internal medicine11th. McGraw-Hill, New York 1987; 1930–1960
   Google Scholar
• Kassell NF, Torner JC. The International Cooperative Study on Timing of Aneurysm Surgery—an update. Stroke. 1984; 15: 566–570
   PubMed Web of Science ®Google Scholar
• Vergouwen MD, Vermeulen M, Roos YB. Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: A systematic review. Lancet Neurol. 2006; 5: 1029–1032
   PubMed Web of Science ®Google Scholar
• Gelmers HJ. The effects of nimodipine on the clinical course of patients with acute ischemic stroke. Acta Neurol Scand. 1984; 69: 232–239
   PubMed Web of Science ®Google Scholar
• Gelmers HJ. Calcium-channel blockers: Effects on cerebral blood flow and potential uses for acute stroke. Am J Cardiol. 1985; 55: 144–148
   Google Scholar
• Gelmers HJ, Gorter K, de Weerdt CJ, et al. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med. 1988; 318: 203–207
   PubMed Web of Science ®Google Scholar
• Martinez-Vila E, Martinez-Lage JM, Llera FG, et al. Nimodipine in acute ischemic stroke. N Engl J Med. 1988; 319: 249–251
   PubMedGoogle Scholar
• Martinez-Vila E, Guillen F, Villanueva JA, et al. Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke. 1990; 21: 1023–1028
   PubMed Web of Science ®Google Scholar
• Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke. 1994; 25: 1348–1353
   PubMed Web of Science ®Google Scholar
• Mathew NT, Rivera VM, Meyer JS, et al. Double-blind evaluation of glycerol therapy in acute cerebral infarction. Lancet. 1972; 2: 1327–1329
   PubMed Web of Science ®Google Scholar
• Gelmers HJ, Hennerici M. Effect of nimodipine on acute ischemic stroke: Pooled results from five randomized trials. Stroke. 1990; 21, IV–81–4
   PubMed Web of Science ®Google Scholar
• Fogelholm R, Palomaki H, Erila T, Rissanen A, Kaste M. Blood pressure, nimodipine, and outcome of ischemic stroke. Acta Neurol Scand. 2004; 109: 200–204
   PubMed Web of Science ®Google Scholar
• Horn EH, Filshie M, Kerslake RW, Jaspan T, Worthington BS, Rubin PC. Widespread cerebral ischaemia treated with nimodipine in a patient with eclampsia. BMJ. 1990; 301: 794
   PubMed Web of Science ®Google Scholar
• Forsman M, Aarseth HP, Nordby HK, et al. Effects of nimodipine on cerebral blood flow and cerebrospinal fluid pressure after cardiac arrest: Correlation with neurologic outcome. Anesth Analg. 1989; 68: 436–443
   PubMed Web of Science ®Google Scholar
• Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am. 1994; 78: 911–934
   PubMed Web of Science ®Google Scholar
• Morich FJ, Bieber F, Lewis JM, et al. Nimodipine in the treatment of probable Alzheimer's disease: Results of two multicentre trials. Clin Drug Invest. 1996; 11: 185–195
   Web of Science ®Google Scholar
• Davidson M, Stern RG. The treatment of cognitive impairment in Alzheimer's disease: Beyond the cholinergic approach. Psychiatr Clin North Am. 1991; 14: 461–482
   PubMed Web of Science ®Google Scholar
• Parnetti L, Senin U, Carosi M, et al. Mental deterioration in old age: Results of two multicenter, clinical trials with nimodipine. Clin Ther. 1993; 15: 394–406
   PubMed Web of Science ®Google Scholar
• Bernhardt T, Kubler J, Erzigkeit H. Impairment of cerebral function in old age: Nimodipine in general practice. Eur J Clin Res. 1995; 7: 205–215
   Google Scholar
• López-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002; 3: CD000147
   PubMedGoogle Scholar
• Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D. Efficacy and safety of nimodipine in subcortical vascular dementia: A randomized placebo-controlled trial. Stroke. 2005; 36: 619–624
   PubMed Web of Science ®Google Scholar
• Jonsdottir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache. 1987; 27: 364–369
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache. 1988; 28: 260–262
   PubMed Web of Science ®Google Scholar
• Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. American Academy of Neurology, St. Paul, Minn. 2001, Available at:,
   Google Scholar
• Lu SR, Liao YC, Fuh JL, Lirng JF, Wang SJ. Nimodipine for treatment of primary thunderclap headache. Neurology. 2004; 62: 1414–1416
   PubMed Web of Science ®Google Scholar
• Zuber M, Touze E, Domigo V, Trystram D, Lamy C, Mas JL. Reversible cerebral angiopathy: Efficacy of nimodipine. J Neurol. 2006; 253: 1585–1588
   PubMed Web of Science ®Google Scholar
• Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache. 1983; 23: 106–109
   PubMed Web of Science ®Google Scholar
• Meyer JS. Calcium channel blockers in the prophylactic treatment of vascular headache. Ann Intern Med. 1985; 102: 395–397
   PubMed Web of Science ®Google Scholar
• Bussone G, Baldini S, D'Andrea G, et al. Nimodipine versus flunarizine in common migraine: A controlled pilot trial. Headache. 1987; 27: 76–79
   PubMed Web of Science ®Google Scholar
• Kamath B, Lettieri J, Krol G, et al. Pharmacokinetics and metabolism of radiolabeled nimodipine. Pharmacol Res. 1987; 4(Suppl. 2)S80
   Google Scholar
• Tietze K, Schwartz ML, Vlasses PH. Calcium antagonists in cerebral/peripheral vascular disorders: Current status. Drugs. 1987; 32: 531–538
   Google Scholar
• Ansell E, Fazzone T, Festenstein R, et al. Nimodipine in migraine prophylaxis. Cephalalgia. 1988; 8: 269–272
   PubMed Web of Science ®Google Scholar
• European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Migraine-Nimodipine European Study Group (MINES). Headache. 1989; 29: 639–642
   PubMed Web of Science ®Google Scholar
• European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Migraine-Nimodipine European Study Group (MINES). Headache. 1989; 29: 633–638
   PubMed Web of Science ®Google Scholar
• Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia. 1985; 5: 39–43
   PubMed Web of Science ®Google Scholar
• Battistella PA, Ruffilli R, Moro R, et al. A placebo-controlled crossover trial of nimodipine in pediatric migraine. Headache. 1990; 30: 264–268
   PubMed Web of Science ®Google Scholar
• de Carolis P, Baldrati A, Agati R, et al. Nimodipine in episodic cluster headache: Results and methodological considerations. Headache. 1987; 27: 397–399
   PubMed Web of Science ®Google Scholar